Related content

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

By Aydin Semra   Dührsen Ulrich   Nückel Holger  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 271-276

Springer Publishing Company

Access to resources Recommend Favorite

Tandem myeloablative ¹³¹I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients

By Deshayes Emmanuel   Kraeber-Bodéré Françoise   Vuillez Jean-Philippe   Bardiès Manuel   Teulon Isabelle   Pouget Jean-Pierre  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1283-1286

Future Medicine

Access to resources Recommend Favorite

Conditioning with treosulfan and fludarabine for patients with refractory or relapsed nonHodgkin lymphoma

By                            

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 773-782

Spandidos Publications

Access to resources Recommend Favorite

Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma

By Sieniawski Michal   Staak Oliver   Glossmann Jan-Peter   Reineke Thorsten   Scheuß Helena   Diehl Volker   Engert Andreas   Josting Andreas  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 107-115

Springer Publishing Company

Access to resources Recommend Favorite

Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma

By Hess Georg   Flohr Thomas   Kolbe Karin   Bonn Sarah   Schuler Martin   Derigs Hans   Huber Christoph  

Annals of Hematology, Vol. 85, Iss. 11, 2006-11 ,pp. : 769-779

Springer Publishing Company

Access to resources Recommend Favorite